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license (http://creativean increased risk of mortality in clinical trials. However, an older postmortem literature suggests that
those with schizophrenia treated in an era of exclusively conventional antipsychotic medications had
a surprisingly low incidence of tau pathology. No previously published studies have investigated the
impact of conventional antipsychotic exposure on tau outcomes in a tau mouse model of AD.
Methods: In two experiments, transgenic rTg (tauP301L) 4510 tau mice were treated with either
haloperidol or vehicle and phosphotau epitopes were quantified using high-sensitivity tau ELISA.
Results: After treatments of 2 and 6 week’s duration, mice treated with haloperidol evidenced a sig-
nificant reduction in tau phosphorylation associated with an inactivation of the tau kinase AMPK.
Discussion: The data suggest that D2 receptor blockade reduces tau phosphorylation in vivo. Future
studies are necessary to investigate the impact of this reduction on tau neuropathology.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Clinicians treating behavioral disturbances related to
Alzheimer’s disease (AD) face a well-publicized dilemma
in the decision of whether to use antipsychotic medications
associated with modest benefits [1–3] but a discomfiting
elevation in the risk of mortality [4]. This class of agents,
including both atypical and conventional antipsychotics,
carries a black box warning from the US Food and Drug
Administration (FDA) cautioning that the use of these med-
ications in dementia with behavioral disturbances leads to an
increased all-cause mortality [5]. Beyond the increased risk
of death, there is evidence from an analysis of the largers have any financial conflicts to disclose.
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Effectiveness-Alzheimer’s Disease (CATIE-AD) study data
that those with dementia treated with the newer atypical an-
tipsychotics experience a more aggressive cognitive decline
than those not exposed [6]. To date, there is no consensus
regarding mechanisms that could explain the deleterious
nonmotor outcomes associated with exposure to these
agents, and it is not clear that the conventional antipsy-
chotics carry the same risk of cognitive decline. Just as
mouse models have been used systematically in AD research
to facilitate a search for a cure, mouse models may be used in
the opposite direction to evaluate the potential negative
neuropathologic consequence of exposure to agents such
as antipsychotics.
The neurofibrillary tangle, derived from paired helical fil-
aments of hyper-phosphorylated tau protein, is the salient
pathologic feature on which the postmortem Braak stagingimer’s Association. This is an open access article under the CC BY-NC-ND
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finding in AD demonstrated to correlate topographically
and quantitatively with clinical symptomatology [8,9].
Neurophysiologically, microtubule-associated tau protein
is thought to participate in the formation and stabilization
of microtubules [10]. Tau exists as a phosphoprotein, and
even in healthy adult brain tau is at least minimally phos-
phorylated [11]; however, what distinguishes AD is the
scope and consistency of phosphorylation of 19 of 441 spe-
cific amino acid sequences along the tau protein resulting in
a particular phosphorylation signature and a greater burden
of phosphotau in AD brain [12]. Specifically, the magnitude
of the difference in phosphotau burden between AD and
healthy adult brain has been estimated to be between a 3–
4X increase in the number of moles of phosphate per mole
of tau [13]. Hyperphosphorylation of tau is believed to
often—but not always—be an integral part of the process
of paired helical filament formation and, ultimately, neurofi-
brillary tangle production, rendering phosphorylation, a crit-
ical step in disease pathogenesis and a potential target of
intervention [14]. In support of studies focusing on pretangle
tau phosphorylation as an outcome in evaluating therapeu-
tics, there is growing speculation that intermediate hyper-
phosphorylated soluble oligomeric tau species may have
the greatest clinical consequence, and that derivative neuro-
fibrillary tangles may not play the primary role [15,16]. The
phosphorylation and dephosphorylation of tau are contro-
lled by the equilibrium of activity of protein kinases
such as GSK3b, cdK5, Akt/PKB, ERK1/2, AMPK, and
phosphatases, such as PP1, PP2A and PP5 [17]. Modifica-
tion of tau kinase or phosphatase activity may be one mech-
anism by which exposures may, depending on direction,
either worsen or ameliorate tau phosphorylation and impact
AD clinical pathology.
Haloperidol, a butyrophenone available at very low cost, is
used commonly in the treatment of psychotic conditions,
including schizophrenia [18], bipolar mania [19], and
delirium [20], in addition to behavior disturbances in AD
[21]. Its clinical efficacy has been attributed to its robust inhi-
bition of dopamine D2 postsynaptic mesolimbic receptors,
whereas side-effects including emotional blunting, cognitive
problems, and extra-pyramidal motor side-effects are
believed to be secondary to mesocortical and striatal postsyn-
aptic D2 receptor blockade [22]. Among antipsychotics, there
is evidence to suggest that haloperidol has the greatest nega-
tive impact on mortality in the dementia population [23,24],
and as a result of these studies, the agent has been decried
as potentially “neurotoxic,” leading some to recommend
avoiding its use altogether in the dementia population [25].
Existing evidence provides conflicting guidance in pre-
dicting the impact of haloperidol exposure on tau pathology
in AD. From one perspective, haloperidol may be expected
to worsen the disease. For instance, a study in neuronal
cell culture suggests that haloperidol does induce tau hyper-
phosphorylation via oxidative stress [26]. If so, could an ac-
celeration of disease leading to increased all-cause mortalitybe related to an exacerbation of tau pathology driven by
increased tau phosphorylation in those exposed to haloper-
idol? From the opposite perspective, although controversial
owing to the limitations of autopsy data derived from an
institutional setting, an older literature has suggested that
AD pathology including tangle density is reduced in schizo-
phrenia [27–32], and that the highly prescribed haloperidol
may be responsible for this neuroprotection [33].
Taken together, although both alternatives to the null hy-
pothesis stipulating higher or lower phosphotau burden
would be viable hypotheses in an in vivo experiment, no pre-
viously published animal studies have investigated the
impact of haloperidol exposure on tau pathology. As such,
the present study was designed to evaluate the impact of
haloperidol on tau phosphorylation in a tau mouse model
of AD while entertaining either directional alternative to
the null hypothesis.2. Methods and materials
2.1. Animals
Animal models of AD are not absolute replicas of the hu-
man disease process; they recapitulate particular neuropath-
ologic features of the disease, most commonly amyloid-b or
tau pathology. The rTg(tauP301L)rTg4510 mouse is a bigenic
strain mouse model of taupathy comprising a transgenic
tauP301L mutation associated with FTDP-17 in exon 10–
placed downstream of a tetracycline-operon-responder
construct [34]. To activate the responder gene requires co-
expression of an activator construct. The activating tetracy-
cline conditional gene expression system has been set down-
stream of a Ca21/calmodulin kinase II (CaMKII) promoter
that limits expression to forebrain structures [35]. While
the derived transgenic tau mutation expressed in the
rTg4510 mouse produces a frontotemporal tauopathy in hu-
mans, as a model of AD tauopathy, the mouse conditionally
drives expression of the tau mutation in the entire forebrain.
The rTg4510 mouse model manifests an aggressive pheno-
type of tau pathology in the forebrain structures in the
form of neurofibrillary tangles with concomitant neuronal
loss and cognitive deficits [35]. rTg4510 breeding pairs
(Tg(tetO-MAPT*P301L), stock #015815 and Tg(Camk2a-
tT stock #003010)) were procured from Jackson Labora-
tories and housed in the Center for Comparative physiology
at the Feinstein Institute for Medical Research where all the
experiments described in this report were conducted. Mice
were housed three to four per cage, with access to food
and water and maintained on a 12-h light/dark cycle (lights
out at 8:30 AM). For each experiment, rTg4510 mice be-
tween 3 and 4.5 months were matched between treatment
(haloperidol) and vehicle (sesame oil) cohorts for age and
balanced for gender. All animal experiments were per-
formed according to procedures approved by the Feinstein
Institute for Medical Research Institutional Animal Care
and Use Committee.
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For the treatment of schizophrenia, in which the rates of
nonadherence to antipsychotic medications can be as high as
40% after an index inpatient psychiatric admission [36],
long-acting injectable depot formulations have been devel-
oped to extend the half-life of medications, dramatically
increasing dosing intervals and reducing relapse [37]. Halo-
peridol decanoate has emerged as the most widely pre-
scribed conventional depot medication owing to its 4-week
human dosing schedule and very convenient conversion for-
mula from oral dosing, with depot monthly dosing generally
around 20 times the daily oral dose, and perhaps for this
reason is one of the long-acting agents associated with the
lowest rate of relapse [37,38]. The decanoate formulation
of haloperidol exists as an ester with high-lipid solubility
in a sesame oil suspension, and is gradually absorbed from
the muscle injection site and then into plasma where ester-
ases gradually convert it via hydrolysis to active drug [39].
Although the half-life is around 4 weeks in humans, the
onset of action occurs within a couple of days [37].
In developing a strategy for the treatment of AD mouse
models with antipsychotic, given the need for subacute or
chronic exposure for pathological outcomes and the desire
for adequate steady-state concentrations, conventional intra-
peritoneal (IP) delivery systems are unappealing owing to
the need for at least daily dosing. Therefore, rather than us-
ing chemical grade haloperidol for IP injections, in the cur-
rent report, pharmaceutical grade haloperidol decanoate was
used for intramuscular (IM) injections. In designing the
dosing regimen, approximating therapeutically relevant
doses in the mouse model was enabled by previous work
in rodents targeting 60%–70% D2 receptor occupancy with
haloperidol decanoate with 21 mg/kg of drug given once
weekly [40–42].
For the 6-week experiment, mice were injected IM in the
hindquarter with haloperidol decanoate 50 mg/mL (Frese-
nius Kabi, Schaumburg, IL) at a dose of 21 mg/kg on day
1, then again at 1 week; 2 weeks; 3 weeks; 4 weeks; 5 weeks;
and sacrificed at 6 weeks. For the 2 week replication, mice
were treated on day 1 with an IM injection in the hind-
quarter at a dose of 21 mg/kg, then again at 1 week, then
again at 2 weeks, and sacrificed at day 16. Mice were moni-
tored twice daily by veterinary technicians for during the
duration of the study for changes in motor behavior and
food and water consumption. While Tmax is unknown for
haloperidol decanoate in mice, as the half-life has been esti-
mated at one week we used day 2 after injection as an esti-
mate of the zenith of antipsychotic drug level for the 2 week
replication.2.3. Tau ELISA
Mice were euthanized via isoflurane overdose and the
brain was removed, and hemisected sagitally. The forebrain
region was dissected, and striatum, cortex, and hippocam-pus were separated. High-sensitivity ELISA using DA31
(Davies lab) (total tau), PHF-1 (pSer396/404) (Davies
lab), CP13 (pSer202) (Davies lab), and RZ3 (pThr231)
(Davies lab) for precise quantification of each phosphotau
species was performed according to previously established
protocols established in our laboratory [43]. After dissec-
tion, the brain was homogenized using appropriate volume
of homogenizing buffer: a solution of Tris buffered saline,
pH 7.4 containing 10-mM NaF, 1-mM NaVO3, and 2-mM
EGTA, including a complete Mini protease inhibitor cock-
tail (Roche). Samples were stored at 280C. Heat stable
preparations were used to obtain soluble tau levels, by add-
ing 5% ß-Mercaptoethanol and 200-mM NaCl to brain ho-
mogenate. Samples were then heated at 100C for
10 minutes, cooled at 4C for 30 minutes, and then centri-
fuged at 13,000 g at 4C for 15 minutes, and supernatants
were collected. Ninety six–well plates were respectively
coated with DA31, PHF1, CP13, and RZ3 at a concentra-
tion of 6 mg/mL in coating buffer, for at least 48 hours at
4C. Plates were washed 3 ! in wash buffer and blocked
for 1 hour at room temperature using StartingBlock (Ther-
moScientific) to avoid nonspecific binding. After the 1 hour
block, each plate was washed 5! and 50 mL of the appro-
priate sample was added to the wells, with 50 mL of DA9-
HRP detection antibody. Plates were incubated O/N
shaking at 4C and washed 9 ! in wash buffer. One-step
ULTRA TMB-ELISA (Thermo Scientific) was added for
300 at room temperature before stopping the reaction with
2M H2SO4. Plates were read with an Infinite m200 plate
reader (Tecan) at 450 nm.2.4. Immunoblotting
Lysates samples were run on 12.5% tris-HCl precast gel
(Biorad). Briefly, samples were boiled for 5 minutes, in
2% SDS and 4% mercaptoethanol, and equal volumes
were loaded, then separated using SDS-PAGE, and trans-
ferred to nitrocellulose membranes. Once transferred,
membranes were probed with antibodies to glycogen syn-
thase kinase (GSK)-3b (cell signaling #9315); Phospho
GSK-3b (Ser9) (cell signaling #5558); Phospho-AMPKa
(Thr172); and AMPKa (cell signaling #2603). Bands
were then detected with either enhanced chemiluminse-
cence (ECL Millipore) or 4-chloronaphthol with 1%
hydrogen peroxide (4CN) depending on their intensity.
Densitometry was performed using ImageJ image process-
ing and analysis (nih.gov).2.5. Statistical analysis
All statistical calculations were performed with Graph-
Pad Prism 5 software. For quantification of phosphotau, re-
sults of ELISA for each antibody (PHF-1, CP13, RZ3)
measured in ug/mg protein was converted to a ratio of phos-
photau/total tau by dividing individual phosphotau antibody
concentrations by the concentration of DA31 (ptau/total
Ha
ldo
l
Se
sa
me
oil
0
10
20
30
40
DA31 (total tau) hippocampus
ug
ta
u/
m
g
pr
ot
ei
n
Ha
lop
eri
do
l
Se
sa
me
oil
0
5
10
15
20
DA31 (total tau) cortex
ug
ta
u/
m
g
pr
ot
ei
n
Ha
lop
eri
do
l
Se
sa
me
oil
0
2
4
6
8
DA31 (total tau) striatum
ug
ta
u/
m
g
pr
ot
ei
n
Fig. 1. Total tau quantified in the cortex, striatum, and hippocampus with DA31 monoclonal antibody in rTg4510 mice treated for 6 weeks with haloperidol
(N 5 20) or sesame oil vehicle (N 5 19). Levels of total tau did not differ significantly between groups.
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variable in statistical analysis, with treatment group (halo-
peridol, sesame oil vehicle) establishing the categorical in-
dependent variable. The means 6 standard error of mean
values of the ptau/total tau was compared for each fore-
brain region (cortex, striatum, hippocampus) between
haloperidol-treated and vehicle-treated mice, and the Stu-
dent t test was calculated for the difference in means to eval-
uate statistical significance. For each statistically significant
difference (P, .05), a Cohen’s d was calculated to estimate
the effect size of the difference. For Western Blot, ImageJ
was used to quantify density of the bands for each antibody,
and this density was converted within the software to a
continuous variable for comparison between groups using
a Student t test.3. Results
3.1. Haloperidol reduces tau phosphorylation
In the first experiment, rTg4510 tau mice were treated for
6 weeks with haloperidol (N 5 20) or sesame oil vehicleTable 1
rTg4510 mice were treated with either haloperidol at a dose of 21 mg/kg/week or
Region
Vehicle, N 5 19,
age 5 20 6 3 weeks
Haloperidol, N 5 20,
age 5 20 6 3 weeks
Cortex
PHF-1/DA31 43.6 6 3.21 33.0 6 1.56
RZ3/DA31 16.3 6 1.44 12.3 6 1.01
CP13/DA31 27.7 6 1.50 24.9 6 1.30
Striatum
PHF-1/DA31 31.8 6 3.42 22.62 6 2.21
RZ3/DA31 13.7 6 1.69 9.05 6 1.29
CP13/DA31 26.8 6 1.84 19.5 6 0.886
Hippocampus
PHF-1/DA31 30.4 6 2.62 28.4 6 2.84
RZ3/DA31 19.3 6 1.29 18.2 6 1.07
CP13/DA31 26.4 6 1.64 25.3 6 1.95
Abbreviation: NS, nonsignificant.
NOTE. Total tau (DA31) and phosphotau were quantified with ELISA. Phospho
404); CP13 (pSer202); and RZ3 (pThr231); and a ratio of ptau/DA31 was calculated
DA31 (arbitrary units) represent the difference between mean ptau/DA31 of vehi
NOTE. P , .05 was considered significant, and for each significant difference,(N 5 19). Injections of haloperidol decanoate were very
well tolerated by the mice, and there were no gross motor ab-
normalities or neuroleptic malignant syndrome in any of the
treated mice. Total tau was measured with DA31 and did not
differ in any brain region between cohort of haloperidol and
vehicle-treated mice (Fig. 1). To quantify a range of tau pa-
thology, we used a panel of highly specific monoclonal anti-
bodies to total and phosphorylated tau developed in our
laboratory [43]. Ser396/404, an epitope known to be phos-
phorylated in early to mature tau aggregates [44], was
measured with PHF-1 antibody; pSer202 was quantified
with CP13, an antibody that identifies early neuritic tau pa-
thology [45]; pThr231, a conformational epitope phosphor-
ylated early in the development of disease and present even
in pre-tangles was quantified with RZ3 [12]. In each brain
region, at each phosphorylation site, ptau/total tau was
decreased in the haloperidol-treated cohort (Table 1). This
difference achieved statistical significance in the cortex
and striatumwith robust effect sizes. To replicate this finding
and to determine whether even briefer treatment with halo-
peridol might reduce levels of phosphotau, rTg4510 tau
micewere again treated with haloperidol (N5 11) or sesamevehicle for 6 weeks
D ptau/total P Effect size (95% CI)
210.6 6 3.51 .005 0.963 (0.299–1.63)
23.96 6 1.74 .029 0.727 (0.079–1.37)
22.85 6 1.98 .160 NS
29.16 6 4.04 .029 0.726 (0.078–1.37)
24.67 6 2.12 .033 0.707 (0.06–1.35)
27.29 6 2.01 .0009 1.16 (0.484–1.84)
21.95 6 3.87 .618 NS
21.13 6 1.67 .502 NS
21.51 6 2.56 .655 NS
tau (ptau) was quantified using an ensemble of antibodies: PHF-1 (pSer396/
for each antibody in each region. Changes (D ptau/total) in the ratio of ptau/
cle-treated mice and mean ptau/DA31 of haloperidol-treated mice.
effect sizes were calculated with 95% confidence intervals.
Table 2
rTg4510 mice were treated with either haloperidol at a dose of 21 mg/kg/week or vehicle for 2 weeks
Region
Vehicle, N 5 9,
age 5 17 6 0.4 weeks
Haloperidol, N 5 11,
age 5 17 6 0.3 weeks D ptau/total P value Effect size (95% CI)
Cortex
PHF-1/DA31 42.1 6 3.14 33.6 6 2.36 28.53 6 3.86 .040 0.994 (0.061–1.928)
RZ3/DA31 24.4 6 1.6 16.9 6 1.06 27.55 6 1.86 .0007 1.824 (0.777–2.87)
CP13/DA31 47.4 6 3.45 28.9 6 1.58 218.5 6 3.56 ,.0001 2.33 (1.29–3.47)
Striatum
PHF-1/DA31 32.1 6 1.79 26.0 6 1.58 26.13 6 2.38 .019 1.16 (0.207–2.11)
RZ3/DA31 14.4 6 0.632 12.28 6 1.46 22.12 6 1.17 .231 NS
CP13/DA31 28.8 6 2.37 22.1 6 1.38 26.72 6 2.63 .0198 1.15 (0.199–2.10)
Hippocampus
PHF-1/DA31 108.2 6 7.53 93.9 6 5.72 214.3 6 9.3 .141 NS
RZ3/DA31 22.99 6 2.61 18.4 6 1.06 24.60 6 2.62 .0965 NS
CP13/DA31 101.3 6 6.078 104.1 6 3.82 12.79 6 6.92 .692 NS
Abbreviation: NS, nonsignificant.
NOTE. Total tau (DA31) and phosphotau were quantified with ELISA. Phosphotau (ptau) was quantified using an ensemble of antibodies: PHF-1 (pSer396/
404); CP13 (pSer202); and RZ3 (pThr231); and a ratio of ptau/DA31 was calculated for each antibody in each region. Changes (D ptau/total) in the ratio of ptau/
DA31 (arbitrary units) represent the difference between mean ptau/DA31 of vehicle treated mice and mean ptau/DA31 of haloperidol treated mice.
NOTE. P , .05 was considered significant, and for each significant difference effect sizes were calculated with 95% confidence intervals.
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tolerated haloperidol decanoatewithout any untoward effect.
The results were essentially unchanged, with no significant
differences in total tau (data not shown) but with robust re-
ductions of phosphotau in the cortex and striatum and
more modest changes in the hippocampus (Table 2). The
discrepancy in the magnitude of the reduction in phosphotau
observed in the cortex and striatum versus the hippocampus
in the haloperidol-treated mice may be the result of the rela-
tive strength of dopaminergic innervation to these regions
and D2 receptor expression [46] or may be a consequence
of regional tau expression in this forebrain expressed model
[35] or an interaction between the two.
3.2. Haloperidol activates the tau kinase GSK-3b and
inhibits AMPK
To explore mechanism, we tested the hypothesis that re-
ductions in phosphotau were driven by GSK-3b phosphory-
lation and inactivation. GSK-3b, among other cellular
functions, is a tau kinase whose inhibition in wild-type
mice happens to have been previously associated with halo-
peridol treatment [47]. Contrary to expectation, we did not
observe an increase in pGSK-3b/total GSK-3b immunoblot
density that would suggest inactivation of the kinase rather a
significant reduction in pGSK-3bwas observed that suggests
an activation of the kinase (Fig. 2). We next tested the hy-
pothesis that the observed effects may be driven by a
decrease in phosphorylated AMP-activated protein kinase
(pAMPK), a tau kinase implicated in the regulation of
cellular metabolic pathways that are known to be affected
by antipsychotic treatment and coupled to downstream
signaling pathways that include GSK-3b (see Discussion).
Results of immunoblot analysis provide evidence that the ra-
tio of activated kinase to total protein, pAMPK/AMPK, is
significantly diminished in haloperidol-treated mice in thecortex and striatum (Fig. 3), whereas immunoblot density
analysis revealed no significant differences in pAMPK/
AMPK in the hippocampus in the same mice (haloperidol
density 1.41/20.14 versus sesame oil 1.21/20.17). These
data are consistent with ptau/total regional effects and sug-
gest that inactivation of AMPK is a potential explanation
for the observed D2 mediated reduction in phosphotau.4. Discussion
The observation made in the current report that haloper-
idol suppresses the phosphorylation of tau protein in an AD
mouse model, does cohere with a previous report of the
impact of D2 blockade on the more primitive transgenic Cae-
norhabditis elegans model of tauopathy. In this model, over
expression of human tau results in a phenotype of worsening
motility in addition to the accumulation of insoluble tau and
neurodegeneration [48]. In a study designed to identify drugs
that target tau-induced neurotoxicity, the Prestwick chemical
library, comprising 1120 generally off-patent compounds
approved by FDA, was screened for the ability of these com-
pounds to suppress motility defects and tau pathology in tau
transgenicC. elegans. [49] Of all of the compounds screened,
six evidenced a significant rescue of motility defect mani-
fested in reduced tau-induced lethargy and improved swim-
ming. Of note, among the six was azaperone, a
butyrophenone antipsychotic drug structurally similar to
haloperidol. Azaperone also reduced tau-aggregation and
tau-induced neuronal degeneration in this model [48]. In an
exploration of mechanism, worms generated that lacked
both dopamine D2-like receptors exhibited improved motility
and a decrease in insoluble tau, pointing to a D2-mediated
pathway of tau aggregation [48]. If so, haloperidol exposure
resulting in D2 blockade may be expected to reduce tau pa-
thology in vertebrates, including tau mouse models.
Fig. 2. Western blots (WB) performed on frontal cortex of mice treated with haloperidol decanoate (N5 11) or vehicle (N5 9) for 2 weeks. (A) No differences
were observed in total GSK-3b. (B) Inactivated pGSK-3b was reduced in haloperidol treated mice. (C) The ratio of inactive/total pGSK-3b/total GSK-3b was
reduced in haloperidol treated mice, suggesting an activation of the kinase. The insert displays typical gel lanes from immunoblots used for quantitative analyses
with ImageJ.
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haloperidol exposure in rTg4510 mice suggests tau kinase
inhibition, and previous research suggests that GSK-3b
could be responsible. GSK-3b is a highly expressed serine/
threonine kinase, described as a “cellular nexus,” [50] en-
meshed in cellular signal transduction of wide-reaching
scope that includes phosphatidylinositol-3-kinase (PI3-K)/
Akt and Wnt cascades [51]. The best evidence for the ther-
apeutic potential of GSK-3b inhibition in the modification
of tau pathology comes from studies of another psychotropic
medication, lithium. Targeted inhibition of GSK-3b in
mouse models of AD with lithium has been shown to reduce
phosphorylation of tau in studies ranging from 4 weeks
[52,53] to 32 weeks [54]. Our initial hypothesis was that
haloperidol was similarly interrupting GSK-3b activity.
Support for this comes from a study focused on the explora-
tion of the AKT-GSK3b signaling pathway in schizophrenia
that evaluated the effect of haloperidol injections on this
pathway in C57Bl/6 wild-type mice [47]. In that study, halo-
peridol injections of 1-mg/kg IP given for 12 days signifi-
cantly increased the phosphorylation of GSK-3b at Ser9.Inhibition of GSK3b is under the control of AKT1-
dependent phosphorylation at Ser9, and increased phosphor-
ylation and deactivation of GSK3b driven by haloperidol
would potentially predict a reduction of phosphotau [55].
In the current report, we observed a reduction in the
inactive pGSK-3b, all the more surprising as this would
predict an increase rather than a decrease in phosphotau.
However, the direction of haloperidol’s effect on the phos-
phorylation of Ser9 may be conditional, and the drug may
not always function as an inhibitor of GSK-3b. Evidence
for this comes from a higher dose and longer duration study
of antipsychotic injections. Haloperidol injections given
daily IP at 10 mg/kg to adult Sprague–Dawley rats for
21 days resulted in a 30% reduction of pGSK-3b in the
frontal cortex, a finding similar to our own results [56]. It
was suggested by the authors of the latter report that this
discrepancy in the influence of haloperidol on GSK-3b
may reflect either a biphasic dose response or perhaps a
biphasic time-course response to haloperidol. In any event,
an alternate explanation for the observed reduction in phos-
photau is required.
Fig. 3. Western blots (WB) performed on frontal cortex of mice treated with haloperidol decanoate (N5 11) or vehicle (N5 9) for 2 weeks. (A) No differences
were observed in total AMPK. (B) Activated pGSK-3b was reduced in haloperidol treated mice. (C) The ratio of active/total pAMPK-3b/total AMPK was
reduced in haloperidol treated mice, suggesting an inactivation of the kinase. The insert displays typical gel lanes from immunoblots used for quantitative an-
alyses with ImageJ.
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metabolic regulatory role with a concurrent influence on
tau-driven AD pathology, has been reported to be activated
in the hypothalamus of mice as a consequence of atypical
antipsychotic exposure [57]. AMPK plays a central role
in cellular energy homeostasis, and is activated by meta-
bolic stress (hypoxia, ischemia, poor nutrient availability)
[58]. The activation of AMPK is associated with increased
food intake; the use of antipsychotic medications (including
haloperidol but more dramatically the atypicals) [59] has
been associated with weight gain and metabolic syndrome,
including an atherogenic lipid profile and emergent dia-
betes mellitus [60]. AMPK activity has been implicated
as a potential medication-induced mediator of the syn-
drome. In support of this, the atypical antipsychotics,
including clozapine, olanzapine, and quetiapine, but not
haloperidol, have been shown to induce AMPK phosphory-
lation in mice (activating the enzyme), whereas polymor-
phisms in AMPK subunit genes have been implicated in
human antipsychotic-induced weight gain [57,61]. Onlyone previous study has investigated the influence of
antipsychotics on AMPK in the brains of a mouse model
of AD. Consistent with expected outcomes, in an amyloid
mouse model of AD, clozapine exposure was shown to
increase AMPK phosphorylation activating the enzyme
[62]. No previously published studies have reported on
AMPK inactivation after haloperidol exposure.
In addition to contributing to metabolic homeostasis,
AMPK is a known tau kinase, and the effect of different clas-
ses of antipsychotic drugs on this kinase may have relevance
for disease prevention or may confer risk depending on the
direction of influence. Work done by two of the authors of
the current report (P.D. and P.M.) has demonstrated that
AMPK phosphorylates tau at multiple sites in and around
the microtubule binding domain, and that in human AD
brain and other tauopathies phosphorylated AMPK was
over-represented in tangle and pre-tangle bearing neurons
[63]. The current report builds on this finding. Most of the
pre-clinical literature on kinase inhibition from the re-
purposing of existing medications in the service of
J. Koppel et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 121-130128phosphotau reduction has been focused on GSK-3b [50,64],
and no previous published studies have reported on
medication-induced inhibition of AMPK activity as a poten-
tial method of phosphotau reduction in vivo. In a manner
congruous with the effect of haloperidol on phosphorylation
of GSKb but with the opposite outcome, at the dose given in
the current report haloperidol appears to inhibit the tau ki-
nase AMPK. These may not be unrelated findings. It has
been demonstrated that PI3K/Akt signaling pathways are
downstream targets of AMPK activity [58]; it may be that
inactivation of AMPK results in reduced downstream phos-
phorylation and activation of GSKb. This is important, as
combining haloperidol (an AMPK inhibitor) with a GSK-
3b phosphorylating agent such as lithium would be expected
to produce dramatic reductions in phosphotau.
The reported data suggest that haloperidol reduces tau
phosphorylation events. This reduction may eventuate in a
reduction in neurofibrillary tangles, an outcome not investi-
gated in the present study. However, the relationship be-
tween tau phosphorylation events and the development of
aggregated tau and neurofibrillary tangles is complex. While
tangles are comprised of hyperphosphorylated tau [65], and
phosphorylation reduces the affinity of tau for microtubules
[66] whether phosphorylation ineluctably leads to increased
tau aggregation is not yet clear. For instance, evidence from
studies investigating lithium in the prevention of tangle for-
mation in tau mice suggests that inhibition of tau phosphor-
ylation via GSK3b ameliorates tau pathology [52].
Nonetheless, there is evidence that phosphorylation of tau
at certain sites may reduce affinity for microtubules while
still inhibiting paired helical filament formation, suggesting
that phosphorylation can be protective [67]. Recently,
chronic treatment with the hypoglycemic metformin was
shown to reduce tau phosphorylation in P301S tau mice
while promoting tau aggregation [68]. Tau dephosphoryla-
tion was demonstrated to be the result of induction of the
tau phosphatase protein phosphatase 2A (PP2A) expression
as a consequence of AMPK/mammalian target of rapamycin
(mTOR) signaling, an effect that seemed to foster rather than
reduce insoluble tau aggregates [68]. It is unknown whether
the reduction in tau phosphorylation associated with halo-
peridol, seemingly mediated by interruption of AMPK activ-
ity, will promote or inhibit tau aggregation and tangle
formation. Longer term studies are required to evaluate these
potentialities.
The potential reduction in tau pathology mediated by
haloperidol may explain some of the early neuropathologic
reports of decreased AD pathology in schizophrenia,
emerging in an era before the introduction of atypical anti-
psychotics. However, these data should be interpreted with
some caution. A sapient critic of the notion of disease pre-
vention with haloperidol in AD would note that haloperidol
is widely prescribed for agitation and psychosis related to
AD, a condition that affects nearly half of those suffering
with disease, and there has been no suggestion of improve-
ment in cognition as a consequence [69,70]. Studies ofhuman disease are certainly required before concluding
that haloperidol has any impact on pathology or cognition.
However, data derived from studies of individuals with AD
treated with haloperidol may not be informative. It may be
that those treated with haloperidol in studies focused on
agitation as an outcome are, in general, at a stage of
disease beyond which the salutary clinical effects of
reduction in phosphorylation of tau are obtained.
It has not previously been reported that D2 receptor
signaling pathways regulate AMPK, a kinase that is typi-
cally activated by cellular conditions of metabolic stress
[71]. AMPK is activated upstream by three kinases—one
of them, Ca/calmodulin-dependent protein kinase kinase b,
is highly expressed in neurons—[72] and inhibited by one
of several phosphatases [73]. Further exploration of D2 re-
ceptor mediated regulation of AMPK activation is necessary
to determine whether D2 blockade is indeed responsible for
the observations made in the current report, or whether there
may be other direct or indirect effects of haloperidol that are
responsible. As the AMPK/mTOR pathway has been shown
to regulate PP2A activity, and as tau dephosphorylation has
been shown recently to be driven by AMPK activation,
future studies should focus on the downstream consequence
of haloperidol-driven inactivation of AMPK on mTOR and
the tau phosphatase PP2A.Acknowledgments
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